NovaBay Pharmaceuticals (NBY) stock slides premarket after 102% surge — dilution risk back on radar

NovaBay Pharmaceuticals (NBY) stock slides premarket after 102% surge — dilution risk back on radar

New York, January 12, 2026, 05:15 EST — Premarket

  • Shares of NovaBay Pharmaceuticals slipped roughly 10% in premarket action.
  • The stock surged past double its previous level on Friday, trading about 10 million shares.
  • Traders are eager for new updates on warrants, conversions, and the share supply.

NovaBay Pharmaceuticals, Inc. shares slipped roughly 10% in early Monday trading, falling to $17.21 after finishing Friday at $19.16. This dip comes after a notable surge in the lightly traded stock on the NYSE American. Stockanalysis

Friday’s surge was extreme, even for a microcap. Shares closed up 102.5%, swinging between $9.69 and $19.95, on roughly 10 million shares changing hands, according to StockAnalysis data. Stockanalysis

This is crucial now, as the stock has morphed into a momentum play within just a few sessions. Such trades hinge heavily on share availability. With thin liquidity, prices can jump sharply on minimal volume—and then flip direction just as quickly.

According to StockAnalysis data, the 20-day average volume stands near 3.0 million shares, with the float hovering around 12.4 million shares. This combination often magnifies both squeezes and selloffs during volume surges. Stockanalysis

Traders keep focusing on the company’s capital structure. In an October filing, NovaBay revealed it sold pre-funded warrants for roughly 5.4 million shares, exercisable after Jan. 1, 2026, pending stockholder approval. The company also noted shareholders authorized the board to execute a reverse stock split anywhere from 1-for-2 up to 1-for-10. Sec

NovaBay revealed in its latest quarterly filing that it had once considered winding down but decided against it. The company is now exploring a pivot toward “emerging financial infrastructure and network-based markets,” with a particular interest in select blockchain-based assets. It also noted that its cash reserves should cover operating costs through at least Nov. 7, 2026. Sec

NovaBay hasn’t released any new comments on the recent stock moves, leaving traders to interpret volume, spreads, and any upcoming disclosures ahead of the open.

But the setup works both ways. Pre-market trading often sees thin volume and wider spreads. Plus, any hint that more shares might enter the market—whether from warrant exercises, preferred stock conversions, or other issuances—can quickly shift the equation for a stock that’s already surged dramatically in a short span.

When the regular session kicks off at 9:30 a.m. EST, traders will focus on whether the stock can maintain last week’s key levels and if the volume remains strong or tapers off.

NovaBay’s fourth-quarter 2025 earnings are expected to drop on March 25, according to MarketScreener. Marketscreener

Stock Market Today

  • Southern Copper Jumps 6.2% on Copper Rally; Signals Potential Upside
    January 12, 2026, 8:19 AM EST. Southern Copper (SCCO) jumped 6.2% in the last session to $170.52 on above-average volume, extending an 8.8% gain over the past four weeks. The move comes as copper climbs, up about 39.2% year over year and trading near a record around $6 per pound amid tighter supply. A softer dollar, expectations of more rate cuts this year, and easing policy in China are supporting metal demand. The company is expected to report EPS of $1.46 for the upcoming quarter, up 44.6% year over year, with revenues seen at $3.62 billion, up 30.1%. The consensus EPS estimate has been revised 17.2% higher in the last 30 days. SCCO carries a Zacks Rank #3 (Hold).
Barclays stock slides on Trump’s 10% credit-card rate cap call as investors size up profit hit
Previous Story

Barclays stock slides on Trump’s 10% credit-card rate cap call as investors size up profit hit

Mereo BioPharma stock steadies premarket as JPM Healthcare Conference puts MREO back in play
Next Story

Mereo BioPharma stock steadies premarket as JPM Healthcare Conference puts MREO back in play

Go toTop